Table 1. Clinical and laboratory data of patients treated with cytoreductive drugs and carrying TP53 mutations.

		Disease type and course					Therapy						Mutations		Follow-up
Therapy group	Sample	Driver mutation a	Sex	Disease phenotype	Age at sampling	Time from dg to study enrollment (mo)	Total therapy length (mo)	Therapy at sampling	HU therapy (mo)	IFN therapy (mo)	ANG therapy (mo)	Busulfan or chemo/radio therapy	Most abundant mutation (VAF %)	TP53 mutations (VAF %)	Follow-up from study enrollment (mo)	Outcome
no HU	MP315	JAK2	M	PV	62	109	89	I	0	0	0	no	0.8	p.Y126D 0.79	39	Alive
	048C	JAK2	M	PV	73	145	96	I	0	96	0	no	0.8	p.E285K 0.82	41	Alive
	JAK1716	JAK2	F	PV	63	111	110	I	0	110	0	no	0.2	p.C238S 0.20	83	Alive
	MP189	CALR+JAK2	F	ET	67	138	112	A	0	0	112	no	2.9	p.P58A 2.90	51	Alive
	MP247	CALR	F	PMF	56	122	119	A	0	5	115	no	0.3	p.Y220C 0.26	48	Alive
	MP155	CALR	F	PMF	61	122	121	A	0	0	121	no	0.2	p.V143E 0.21	52	Alive
	227A	CALR	M	PMF	72	154	123	I	0	123	0	CH	0.3	p.A138V 0.26	10	Dead
	65A	CALR	F	ET	70	158	152	IA	0	152	11	no	1.7	c.376-2A>G 1.71; p.R273H 0.2	121	Alive
	186A	JAK2	F	ET	80	180	175	I	0	175	0	no	8.3	c.454dupC 8.27	37	Dead-AMLb
	221A	CALR	M	ET	69	180	179	I	0	179	0	no	2.2	p.I162S 2.24	118	Alive
HU <4y	MP15	JAK2	M	PV	66	84	84	I	17	77	0	no	4.4	p.Y220C 4.4	62	Alive
	MP160	JAK2	M	ET	69	61	18	H	18	0	0	no	0.2	p.P142R 0.23	52	Alive
	MP68	JAK2	F	MPN	70	58	56	H	47	0	9	no	6.9	p.R248Q 6.90; p.A159V 6.40; p.P151R 1.73; p.I195S 0.24; p.R273H 0.23	44	Dead-AMLc
HU ⩾4y	MP326	JAK2	F	PV	58	80	48	H	48	0	0	no	0.6	p.Y220C 0.55	39	Alive
	MP345	JAK2	M	PV	68	50	48	H	48	0	0	no	1.1	p.S215R 1.10	38	Alive
	MP302	JAK2	F	PV	71	231	65	H	56	0	0	B	0.4	p.G199E 0.44	29	Alive
	MP319	JAK2	M	PV	61	62	57	HA	57	0	32	no	0.4	p.R273H 0.37	28	Alive
	MP168	JAK2	F	PV	68	86	57	H	57	0	0	no	1.0	p.H179R 0.95	49	Alive
	MP153	JAK2	M	PV	63	62	61	HA	60	0	61	no	0.2	p.R213G 0.23	51	Alive
	MP96	JAK2	F	PV	55	64	62	H	62	0	0	no	0.5	p.I195T 0.51; p.R282W 0.20	54	Alive
	MP327	JAK2	F	ET	73	125	64	H	64	0	0	no	0.5	p.R273H 0.47	39	Alive
	MP317	CALR	M	PMF	81	65	65	H	65	0	0	no	0.8	p.V216M 0.83; p.H179R 0.25	17	Dead
	MP63	JAK2	F	ET	68	79	69	H	69	0	0	no	0.2	p.M246V 0.20	53	Alive
	MP5	JAK2	M	PV	68	70	70	H	70	0	0	no	0.3	p.I195T 0.26	64	Alive
	MP10	JAK2	M	PMF	79	77	76	H	76	0	0	no	10.5	p.G245S 10.50; p.R158H 0.54; p.H168R 0.29; p.F134L 0.23; p.Y234H 0.21	46	Dead-expansiond
	MP307	MPL	F	PV	82	103	76	H	76	0	0	no	0.2	c.572_574del 0.21	40	Alive
	MP369	JAK2	F	PV	73	84	81	H	81	0	0	no	1.4	p.T170M 1.39	35	Alive
	MP246	JAK2	F	ET	71	108	103	A	82	0	30	no	0.2	p.D259H 0.2; p.G245S 0.2	48	Alive
	MP314	JAK2	F	PV	69	233	92	H	86	0	0	B	1.3	p.C242Y 1.26; p.G245D 0.35	39	Alive
	MP8	JAK2	M	PV	82	92	90	H	90	0	0	no	0.2	p.R175H 0.24	49	Dead
	MP356	JAK2	F	ET	69	109	91	H	91	0	0	no	1.6	p.R248Q 1.64	37	Alive
	MP230	JAK2	M	MPN	70	96	96	H	96	0	0	no	0.5	p.R248Q 0.50; c.512_514dup 0.22; p.V274G 0.20	22	Dead
	MP289	JAK2	F	PV	61	265	140	no	98	42	0	no	3.3	p.R213* 3.29; p.I251T 0.93; p.Y234H 0.67	39	Alive
	MP273	JAK2	F	ET	75	111	111	H	111	0	0	no	0.3	p.C176S 0.31; p.S240G 0.22	47	Alive
	MP229	JAK2	F	PMF	85	112	112	H	112	0	0	no	1.0	c.376-1G>A 0.95	49	Alive
	MP363	JAK2	M	ET	87	117	112	H	112	0	0	no	0.3	p.R248Q 0.29	37	Alive
	MP7	JAK2	F	PV	69	133	130	H	121	9	0	no	0.5	p.I255T 0.46	64	Alive
	MP329	JAK2	F	ET	73	162	142	H	142	0	0	no	2.6	p.R248W 2.61	27	Alive
	MP250	JAK2	F	PV	74	152	152	H	152	0	0	no	0.4	p.W91* 0.36	11	Dead
	MP2	CALR	F	ET	68	195	186	HA	169	11	110	no	11.6	p.E286K 11.60; p.R248Q 0.45	67	Alive
	MP324	JAK2	M	PV	72	255	255	H	255	0	0	no	0.3	p.T253A 0.26	15	Dead

Abbreviations: A/ANG, anagrelide; B, busulphan; CH, chemotherapy; ET, essencial thrombocythemia; F, female; H/HU, hydroxyurea; I/IFN, interferon alpha; M, male; mo, months; PMF, primary myelofibrosis; PV, polycythemia vera; R, radiotherapy; y, years.

^aAll three driver genes (JAK2 V617F+exon 12, CALR exon 9 and MPL exon 10) were sequenced in all patients with TP53 mutation.

^bSample from leukemic transformation not available.

^csAML JAK2-wt/TP53-wt.

^dClonal expansion without leukemic transformation.